Author details

Full Name

Giordano Caponigro

Affiliation

ORCID

Career Start Year

1993

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36947734	Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.		2023
36961816	Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.		2023
35905710	High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.	Cell Rep	2022
33355204	LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.	Clin Cancer Res	2021
33046519	Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.	Clin Cancer Res	2021
32292577	Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.	Oncotarget	2020
32076487	Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.	Oncotarget	2020
31439712	Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.	Mol Cancer Ther	2019
30559381	Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.	Nature	2019
31068700	Next-generation characterization of the Cancer Cell Line Encyclopedia.	Nature	2019
31068384	SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.	Mol Cancer Ther	2019
29505033	SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.	Nature Medicine	2018
30443290	The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.	Oncotarget	2018
29483135	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.	Cancer Discov	2018
29343524	Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.	Cancer Res	2018
27729458	Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma.	Clin Cancer Res	2017
28838206	Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib.	Annals of Oncology	2017
28655712	BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.	Mol Cancer Res	2017
28611198	Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant Melanoma.	Clin Cancer Res	2017
29141225	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.	Cell Rep	2017
27986745	Dual <i>ALK</i> and <i>CDK4/6</i> Inhibition Demonstrates Synergy against Neuroblastoma.	Clin Cancer Res	2017
27659046	High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells.	Cancer Res	2016
26673799	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.	Clin Cancer Res	2016
24076604	Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.	Nat Genet	2013
24045179	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.	Clin Cancer Res	2013
22460905	The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.	Nature	2012
21358737	Advances in the preclinical testing of cancer therapeutic hypotheses.	Nature Reviews Drug Discovery	2011
21107320	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.	Nature	2010
19177017	Single-vector inducible lentiviral RNAi system for oncology target validation.	Cell Cycle	2009
18403640	Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death.	Molecular Cancer Research	2008
12766481	A genetic selection method for expression products that induce apoptosis in adherent mammalian cell lines.	Apoptosis	2003
12890608	Functional analysis of expressed peptides that bind yeast STE proteins.	J Biotechnol	2003
11754477	Expression levels of transdominant peptides and proteins in Saccharomyces cerevisiae.	Yeast	2002
11314269	Template selection during manipulation of complex mixtures by PCR.	Biotechniques	2001
11590620	Enrichment during transdominant genetic experiments using a flow sorter.	Cytometry	2001
11580863	Transcriptional transactivation by selected short random peptides attached to lexA-GFP fusion proteins.	BMC Mol Biol	2001
11166652	Peptide inhibitors expressed in vivo.	Curr Opin Chem Biol	2001
9421525	Green fluorescent protein as a scaffold for intracellular presentation of peptides.	Nucleic Acids Res	1998
9636180	Transdominant genetic analysis of a growth control pathway.	Proc Natl Acad Sci U S A	1998
8757137	An essential component of the decapping enzyme required for normal rates of mRNA turnover.	Nature	1996
8932387	mRNA turnover in yeast promoted by the MATalpha1 instability element.	Nucleic Acids Research	1996
8852902	Mechanisms and control of mRNA turnover in Saccharomyces cerevisiae.		1996
7557393	Multiple functions for the poly(A)-binding protein in mRNA decapping and deadenylation in yeast.	Genes and Development	1995
8355674	A small segment of the MAT alpha 1 transcript promotes mRNA decay in Saccharomyces cerevisiae: a stimulatory role for rare codons.	Molecular and Cellular Biology	1993